At first glance, second sourcing sounds like a procurement topic. A product is already in production, an additional supplier is identified, prices are compared, samples are ordered, and the new source is eventually qualified. In MedTech, I believe this view is too narrow.
A second industrial pathway
A second source is not simply an alternative place to order from. It is a second industrial pathway to a regulatory-compliant medical device. And that is precisely why establishing one is often far more complex than it initially appears.
A new partner must be able to do much more than read a drawing and reproduce a product geometrically. Materials, manufacturing processes, tolerances, surface treatments, measurement methods, validations and documentation all need to be understood—and, where necessary, established again.
Depending on the product, additional requirements may include sterilization, packaging, biocompatibility and other regulatory considerations. This means that even if two products appear identical on paper, the processes behind them do not necessarily have to be identical.
Resilience has to be designed beforehand
That is where one of the biggest challenges begins. Many second-source projects are initiated only after a problem has already emerged: capacity constraints, supply disruptions, rising costs or geopolitical risks. Suddenly, speed becomes critical.
In my experience, that is the wrong time to start. Resilience is not created during a crisis. It has to be designed beforehand.
The questions strategic second sourcing must answer
Strategic second sourcing starts by identifying which components are truly critical, where regulatory or technical switching barriers exist and which processes require particularly long qualification periods.
It also requires a realistic view of scale: how quickly could a second partner increase production, and how much business does that partner need to make the relationship commercially attractive in the long term?
Qualification alone does not create resilience
A second source needs to do more than work technically. It must be commercially viable, regulatory robust and operationally ready to scale.
A supplier that was qualified once but receives almost no volume for the next five years may formally be a second source—but that does not necessarily make it a resilient alternative.
Procurement becomes part of product strategy
This also changes the role of procurement. The lowest purchasing price and the most resilient supply chain are not necessarily the same thing.
Strategic sourcing in MedTech therefore means evaluating cost, quality, technology, capacity and risk together.
Second sourcing does not begin with an RFQ. It begins with the question of which capabilities a company needs to remain able to supply tomorrow.